Abstract
Clinical effects of doxifluridine (group A, 600 mg/body/day; group B, 800 mg/body/day) combined with radiotherapy and immunotherapy were evaluated in patients with advanced cancer of the uterine cervix. Response rates were 84.2% (16/19 patients) in group A and 100% (18/18 patients) in group B, respectively (p=0.230). There was no significant difference in adverse reaction incidence between the methods but significantly higher grade adverse reaction were observed in group B than in group A (p=0.048). Time to progression (TTP) was longer in group B than in group A (p=0.081). The optimal 5'-DFUR dose was 800 mg/body (group B), by which higher grade adverse reactions were fully controlled and TTP was prolonged.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Combined Modality Therapy
-
Confidence Intervals
-
Disease Progression
-
Disease-Free Survival
-
Female
-
Floxuridine / adverse effects
-
Floxuridine / therapeutic use*
-
Humans
-
Middle Aged
-
Neoplasm Staging
-
Sizofiran / adverse effects
-
Sizofiran / therapeutic use*
-
Survival Rate
-
Time Factors
-
Uterine Cervical Neoplasms / immunology
-
Uterine Cervical Neoplasms / mortality
-
Uterine Cervical Neoplasms / pathology
-
Uterine Cervical Neoplasms / radiotherapy
-
Uterine Cervical Neoplasms / therapy*
Substances
-
Antineoplastic Agents
-
Floxuridine
-
Sizofiran
-
doxifluridine